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Increased use of nonnucleoside reverse transcriptase inhibitors (NNRTIs) in pregnant and breastfeeding
women will result in fewer children infected with human immunodeficiency virus (HIV). However, among
children infected despite prevention of mother-to-child transmission (PMTCT), a substantial proportion will
acquire NNRTI-resistant HIV, potentially compromising response to NNRTI-based antiretroviral therapy
(ART). In countries scaling up PMTCT and pediatric ART programs, it is crucial to assess the proportion of
young children with drug-resistant HIV to improve health outcomes and support national and global decision
making on optimal selection of pediatric first-line ART. This article summarizes a new World Health Organization
surveillance protocol to assess resistance using remnant dried blood spot specimens from a representative
sample of children aged <18 months being tested for early infant diagnosis.
As of December 2010, 3.4 million children aged
,15 years were estimated to be living with human
immunodeficiency virus (HIV). In 2010, an esti-
mated 390 000 (range, 340 000–450 000) children
aged ,15 years were newly infected with HIV, and
250 000 (range, 150 000–360 000) died from AIDS-
related diseases [1].
The World Health Organization (WHO) and the
US President’s Emergency Plan for AIDS Relief support
countries to scale up services for the prevention of
mother-to-child transmission (PMTCT) of HIV. In
2010, 48% (range, 44%–54%) of pregnant women
living with HIV in low- and middle-income countries
received the most effective regimens for PMTCT
(excluding single-dose nevirapine [NVP]) [1].
Current WHO PMTCT guidelines [2] recommend
that, in addition to women requiring antiretroviral
therapy (ART) for their own health, pregnant women
who do not require ART should be initiated on a pro-
phylactic regimen as early as 14 weeks’ gestation. Infants
born to women receiving ART either for their own
health or as prophylaxis should also receive standard
prophylaxis with daily zidovudine (ZDV) or NVP
started at birth and continued to 4–6 weeks regardless
of breastfeeding. For breastfed infants of mothers not
receiving ART, daily NVP prophylaxis should be started
at birth and continued until 1 week after stopping
breastfeeding.
As recommended by WHO, infants known to be
exposed to HIV should receive a diagnostic HIV poly-
merase chain reaction (PCR) test at 4–6 weeks of age
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using dried blood spots (DBSs), or at the earliest opportunity
thereafter. For breastfed children, repeat HIV testing 6 weeks
after cessation of breastfeeding (when the child is ,18 months
old) is recommended [3]. Additionally, WHO recommends
that all HIV-infected infants and children aged #24 months
start ART at time of diagnosis [3]. The public health approach
to global ART scale-up is based on use of 2 nucleoside reverse
transcriptase inhibitors (NRTIs) in combination with a non-
nucleoside reverse transcriptase inhibitor (NNRTI). This anti-
retroviral (ARV) drug combination is widely available, relatively
inexpensive, and available in generic formulations and co-
formulated tablets for pediatric populations.
WHO recommends that children with previous exposure to
an NNRTI, either because their mothers received an NNRTI-
based regimen during pregnancy, labor and delivery, or
breastfeeding, or because they received an NNRTI directly,
should initiate an ART regimen that includes the protease in-
hibitor lopinavir/ritonavir (LPV/r) [3].
The implementation of pediatric ART with ritonavir-boosted
protease inhibitor (PI) regimens, which are commonly reserved
for second-line ART, presents a number of challenges that
limit ART success, including limited availability of PIs, relatively
high cost, poor palatability, need for cold chain supply, in-
teraction with rifampicin used for treatment of tuberculosis
coinfections, and association with long-term metabolic com-
plications [4–6]. In addition, a large proportion of children
starting ART do not have documentation of previous PMTCT
exposure and therefore are blindly initiated on a standard NVP-
containing regimen [3]. Although NNRTI-based PMTCT regi-
mens reduce HIV infection risk in infants and children, the
increased risk of acquiring drug-resistant HIV infection in
children who become infected despite PMTCT, particularly
with extended NVP prophylaxis [7], poses a challenge.
In children, NNRTI-resistant HIV can be selected by ex-
posure to NNRTIs used for maternal ART or child prophylaxis
in the antenatal, intrapartum, and postpartum periods (in-
cluding during breastfeeding). Furthermore, primary infection
with NNRTI-resistant virus through mother-to-child trans-
mission in utero, peripartum, and via breastfeeding is docu-
mented [8]. A meta-analysis [9] of 7 studies of HIV-exposed
infants who became infected despite NVP PMTCT showed
an overall prevalence of NNRTI HIV drug resistance (HIVDR)
in 52.6% of infants (N 5 201; 95% confidence interval [CI],
37.7%–67.0%) at 4–8 weeks following NVP exposure using
standard HIV genotyping assays. The risk of acquiring NNRTI-
resistant virus is increased further when NVP is given daily
for prophylaxis against transmission while breastfeeding.
Infants who received 6-week extended-dose NVP during
breastfeeding were significantly more likely to carry NNRTI
resistance mutations detected by standard genotyping than
those who received single-dose NVP (sd-NVP) [7, 10]. NNRTI
resistance was reduced to 16.5% when NVP prophylaxis was
combined with ZDV or ZDV plus lamivudine (3TC). The
addition of extended ZDV to extended NVP prophylaxis also
reduces the risk of NVP resistance for infants infected in utero
[11]. A negative correlation between the level of detected
NVP resistance and infant age is reported (P, .001) [12], which
may have implications for timing of reuse of NVP for ART
in infants with prior NNRTI exposure [13, 14].
Concerns have been raised for infants exposed to NRTI
prophylaxis or whose mothers are receiving NRTIs for ART
and are breastfeeding. In the Pediatric AIDS Clinical Trials
Group Protocol (PACTG) 076 study [15] in which NRTIs were
used for PMTCT, no NRTI resistance was detected in infected
infants. However, the PACTG185 study [16] showed high ZDV
resistance prevalence among infected infants whose mothers
had ZDV PMTCT. In the Stopping Infection from Mother-
to-Child via Breastfeeding in Africa study infants, prophylaxis
with 3TC for prevention of breast milk transmission resulted
in acquisition of the M184V/I mutation in 69% of infants,
which was no longer detectable 5 months after discontinuation
of 3TC [17]. The Kisumu Breastfeeding Study, a single-arm
open-label PMTCT trial, assessed the safety and efficacy of
ZDV, 3TC, and either NVP or nelfinavir given to HIV-infected
women from 34 weeks’ gestation through 6 months of breast-
feeding. The study evaluated the emergence of maternal ARV-
associated resistance among 32 HIV-infected breastfed infants.
Genotypic resistance was detected among 9 of 9 (100%) and 7 of
15 (47%) infected infants whose mothers were receiving nelfi-
navir and NVP, respectively [18]. The commonest mutations
conferred resistance to 3TC (M184V) and NVP (K103N). No
major PI mutations were detected [18]. The pattern of muta-
tions detected suggests that drug resistance most likely arose
through exposure of the infants to low levels of ARV drugs in
breast milk rather than through mother-to-child transmission
of drug-resistant virus. Given the limited availability of alter-
native drugs for infants in resource-limited settings, the authors
suggest that provision of the standard WHO-recommended
first-line NRTI backbone, which includes 3TC, with en-
hanced monitoring of the infant to ensure virologic suppres-
sion, could be considered. Such an approach should reduce
both illness and morbidity among infants who become HIV
positive through breastfeeding. Multiclass resistance mutations
to both NNRTI and NRTI were detected in 11 of 37 breast-
feeding infants whose mothers initiated NNRTI-based ART
for their own health postpartum. The infants had received
either sd-NVP or extended NVP prophylaxis [19, 20]. Initia-
tion of maternal ART within 14 weeks of delivery was asso-
ciated with detection of multiclass HIVDR in breastfeeding
infants [21].
Selection of HIVDR may be due to low levels of ARV expo-
sure to the infant or child through breastfeeding, although
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studies are limited. NVP levels in breast milk were found to
be measurable for up to 16 days after maternal sd-NVP [22].
Although NNRTI exposure in breast milk may prevent in-
fection, it may also select for drug-resistant virus, depending
on the level to which the child is exposed. Suboptimal levels
of NNRTIs have been documented in breast milk [23–24], but
in the Kisumu Breastfeeding Study, NVP and 3TC were detected
in breastfeeding infants at levels sufficient to suppress virus
replication. Drug-resistant HIV may also be transmitted
through breast milk; NNRTI-resistant virus has been detected
in breast milk of women who received intrapartum sd-NVP
[25]. The risk of NNRTI resistance transmission is reduced
when sd-NVP prophylaxis in women is combined with a 7-day
course of ZDV/3TC (‘‘tail’’) [26].
Selection of drug-resistant HIV during PMTCT has im-
portant implications for ART in children in whom pro-
phylaxis fails. In an initial study in a small number of infants,
sd-NVP–exposed infants were significantly more likely to fail
ART when started on NVP-based regimens [27, 28]. More
recently, the PACTG P1060 trial [29], a large randomized
controlled trial conducted in 6 African countries, comparing
an LPV/r-based ART regimen to a NVP-based ART regimen
in HIV-infected children between 6 and 36 months of age
who previously received sd-NVP for PMTCT, showed that
LPV/r-based ART was superior to NVP-based ART in pre-
venting virologic failure/discontinuation of ART (odds ratio
[OR],18.6; P 5 .02). In this study, baseline NVP resistance
was detected in 12% (18 of 148) of children studied and pre-
dicted ART failure in the NVP arm (P5 .02 for the interaction
between treatment and baseline NNRTI resistance).
NVP may be used in ART for sd-NVP–exposed children if
the NVP-based ART is introduced after HIV replication is ini-
tially controlled with LPV/r-based therapy according to the
Nevirapine Resistance Study (NEVEREST) [13]. In modified
intent-to-treat analyses, more children who switched to NVP
maintained HIV RNA ,50 copies/mL through week 24 post-
randomization compared with those continuing LPV/r (65.6%
vs 49.5%; P5 .02). However, fewer children in the switch group
than in the control group maintained HIV RNA ,1000 copies/
mL (84.9% vs 96.8%; P 5 .007). Similar findings were observed
at week 156 postswitch by Kuhn [30]. Moorthy et al [14] showed
that levels at which NNRTI drug resistance mutations were
present in pretreatment plasma ($25%, and therefore detected
with standard clinical genotyping assays) at the start of LPV/r-
based ART in the infants in the NEVEREST study was predictive
of ART failure with use of NVP-based ART.
In summary, scale-up of PMTCT efforts following WHO
guidelines should result in a decrease in pediatric HIV in-
fection. However, the increased use of ARVs for prophylaxis
in children and pregnant/breastfeeding women or as part
of ART regimens in women will lead to substantial increases
in the proportion of children infected despite PMTCT, ac-
cording to numerous studies [7–11]. Response to NNRTI-
based first-line ART in HIV-infected children is compromised
by prior exposure to NNRTIs for PMTCT and for maternal
health, particularly in infants initiating ART immediately after
diagnosis. Despite the revised 2010 treatment guidelines
advocating LVP/r-based ART as the regimen of choice for
HIV-infected children with prior NNRTI exposure, in many
countries NNRTI-exposed children are still initiated on
NNRTI-based regimens. Reasons include cost and availability
of PIs and, in many instances, absence of adequate docu-
mentation of previous PMTCT exposures to justify initiation
with PI-based regimens.
In settings scaling up PMTCT and pediatric ART programs,
it is important to assess the proportion of children with HIVDR
and therefore at risk for premature virological failure due to
previously selected drug-resistant virus.
Despite the clear need, surveillance to assess ‘‘real-world’’
HIVDR among HIV-infected children aged ,18 months has
not been implemented to date on a large scale due to cost and
logistical constraints. However, scale-up of early infant diag-
nosis (EID) using DBSs [31–34] provides a unique surveillance
opportunity to test remnant specimens for drug resistance.
The WHO, HIVResNet, and the Centers for Disease Control
and Prevention developed a surveillance method to assess
HIVDR to specific ARVs among children ,18 months of age
and newly diagnosed with HIV in resource-limited countries.
This surveillance activity is designed to be integrated into na-
tional surveillance strategies and repeated over time to capture
evolving drug resistance scenarios as PMTCT regimens change
and coverage improves. Results from these surveys will support
decisionmaking on optimal selection of pediatric ART regimens.
Because the survey uses remnant DBSs and routinely col-
lected information from children being tested for EID, we
evaluated survey feasibility and retrieved information to
support development of survey methods by assessing labora-
tory capacity for EID through a questionnaire, which was
sent to 20 African countries in 2010. Among the 14 that re-
sponded, only 2 countries (Liberia and Sierra Leone) reported
no EID capacity. In the remaining 18 countries, between 1 and
11 laboratories provide EID (Figure 1). In total, 93% of the
countries reported that basic demographic data such as age
of the child, sex, date of birth, and date and site of specimen
collection are recorded on the laboratory requisition accom-
panying the DBSs to the EID laboratory; however, only 43%
recorded PMCTC exposure (unpublished data, WHO).
METHODS
Because EID methods using DBSs are being implemented in
many resource-limited countries and because of the suitability
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of DBSs for HIVDR genotyping [35–37], DBS is the specimen
type selected for this survey. The survey method is retrospective
and uses remnant DBSs from HIV-infected children aged
,18 months stored at EID laboratories. Demographic and
clinical information are abstracted from laboratory requisition
accompanying DBSs. Patient variables are presented in Table 1.
DBSs collected for EID and genotyped will originate from
routine follow-up of HIV-exposed children through PMTCT
programs, maternal and child health clinics, or antenatal clinics;
HIV testing of symptomatic children presenting to maternal and
child health clinics, hospitals, or other medical facilities; and
testing of children in provider-initiated testing and counseling
sites or voluntary counseling and testing sites.
Because surveillance is conducted retrospectively using rem-
nant DBSs, specimens must have been stored and handled ac-
cording to WHO recommendations [38]. In countries where
DBSs have not been stored according to WHO guidelines,
specimen shipment and storage may need to be adjusted prior
to survey implementation.
HIVDR Testing
The relevant portions of the reverse transcriptase region of the
pol gene of HIV will be sequenced from DBSs using standard
sequencing methods following standard WHO methods.
Survey Inclusion Criteria
Participant inclusion/exclusion criteria are described in Table 2.
Sample Size, Laboratory, and Specimen Selection
In some resource-limited settings, all EID DBSs are tested by
1 national laboratory, whereas other countries have many EID
laboratories. When possible, all laboratories performing HIV
EID will participate in pediatric HIVDR surveillance and will
contribute to the overall sample. If only a subset of labora-
tories participate, a sample of those will be selected based on
probability proportional to size cluster sampling. In each par-
ticipating laboratory, eligible DBSs will be sampled using simple
random sampling without replacement.
The sample size calculation is based on the assumption that
the true HIVDR prevalence is 50% and with CIs of 6 7%.
Prevalence of 50% is the most conservative assumption, yielding
the largest sample size and most precise CIs. Sequence ampli-
fication success from DBSs is assumed to be 80%. Using the
normal approximation to a binomial distribution in PASS
2008 software (http://www.ncss.com), a 95% CI of 14% (67%)
for a prevalence of 50% requires a sample size of 196. Because
the amplification rate is expected to be 80%, the effective
sample size is 196/0.85 245. In countries where there is only
1 EID laboratory, DBSs from eligible children are selected until
a sample size of 245 is reached. In countries where DBSs
are obtained from.1 laboratory, the laboratories are assumed to
be representative of geographic regions and will be treated as
strata.
In countries conducting this survey for the first time with
no background information on variation in HIVDR prevalence
among different EID laboratories, a design effect of 2, which
represents the ratio of variance from a stratified sample to the
variance of a simple random sample, is applied. Therefore, in
countries with .1 laboratory contributing specimens, the final
effective sample size for the country will be 245 3 2 5 490
(protocol available at www.who.int/hiv/drugresistance/).
Figure 1. Laboratories providing early infant diagnosis (EID) services in 20 African countries (May 2010).
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Ethical Considerations
Remnant DBS specimens will be tested anonymously and no
personal identifiers will be abstracted; a ‘‘nonresearch’’ waiver
will be requested from institutional review boards/ethics review
committees.
Statistical Analysis
The prevalence of HIVDR mutations leading to a classification
of high, intermediate, or low levels of HIVDR by drug and
drug class as determined by the Stanford algorithm [39] will be
determined.
HIVDR prevalence will be estimated with 95% CIs based on
exposure to PMTCT (yes/none/unknown). If sample sizes are
sufficient and patient data are available, separate analyses
will be performed evaluating the association of HIVDR with
specific PMTCT regimens.
DISCUSSION
Despite the revised 2010 WHO recommendations, in many
countries, children are started on NNRTI-based regimens
regardless of previous NNRTI exposure, because of cost and
feasibility. It is important to assess the proportion of children
who carry mutations potentially associated with NNRTI-based
regimen failure. Even in countries where PI-based regimens
are offered to children with documented exposure to NNRTI,
PMTCT NNRTI exposure may not be routinely recorded or may
be incorrectly reported as ‘‘none’’ or ‘‘unknown’’ and children
may be inappropriately started on NNRTI-based regimens.
NNRTI resistance in children is often found at higher rates
in observational studies as opposed to clinical trials. Ex-
planations include insufficiently strict methodology for accurate
evaluations, varying periods of exposure, or real-world con-
ditions such as suboptimal adherence to ARVs. It is important
to perform HIVDR surveillance and to monitor the im-
plementation of the PMTCT program in the field to support
optimal pediatric ART strategies. This survey will provide de-
scriptive evidence of HIVDR in HIV-infected children and
may provide information on association of different PMTCT
ARV exposures and HIVDR, which will inform future WHO
PMTCT ARV guidelines. The survey requires minimal infra-
structures, resources, and personnel and is designed to be easily
implemented, making use of remnant specimens and patient
information routinely captured and transferred to EID laborato-
ries. The simple design of this survey should encourage coun-
tries to implement it at regular intervals in order to monitor
changes in HIVDR prevalence over time.
This protocol does, however, have limitations. First, in many
countries, documentation of infant and child PMTCT exposures
on laboratory forms accompanying DBSs for EID testing is in-
complete, thus limiting ability to test association between ARV
exposure and HIVDR emergence. Second, in many settings
DBSs may not be properly collected, transported, or stored, thus
lowering amplification efficiency, which may lead to over- or
underestimation of resistance. Third, if EID coverage at the
national level is not high, survey results may have limited gen-
eralizability to HIV-infected children aged ,18 months in
that country. Additionally, if EID coverage at the national level
varies among sites or between geographic regions that offer
different PMTCT regimens, overall HIVDR prevalence may
be over- or underestimated.
Table 2. Participant Inclusion and Exclusion Criteria
Inclusion criteria:
1. DBS tested HIV positive by PCR from a child ,18 months of age
2. If DBS for PCR is collected from a child at different time points,
these should be clearly labeled with a unique ID so that the child
is not counted more than twice. The most recent DBS specimen
from the child is selected for genotyping.
3. At least 1 viable remnant spot is available (2–4 DBSs optimal)
4. From time of blood draw, DBS has been stored no longer than
14 days at ambient temperature, then stored at 220C or 280C
with no thawing before genotyping.
Exclusion criteria:
1. DBS from children $18 months of age
2. Child is receiving $3 ARV drugs for the purpose of treatment of
HIV at time of specimen collection
Abbreviations: ARV, antiretroviral; DBS, dried blood spot; HIV, human immuno-
deficiency virus; PCR, polymerase chain reaction.
Table 1. Required and Optional Survey Variables
Required variables:
1. Date of birth (if not available, age of child in months at time of
blood draw)
2. Sex
3. Site name where DBS was collected
4. Site type where DBS was collected
5. Date of DBS collection
6. Date DBS frozen at 220C or 270C
7. Child receiving ART (not PMTCT) at time of specimen collection
(yes/no)
8. Date of PCR testing
9. Date of genotyping
Optional variables:
1. Exposure to breastfeeding at time of specimen collection
2. Name of ARV drugs received by mother antepartum/intrapartum/
postpartum/during breastfeeding
3. Name of ARV drugs received by infant/child postpartum/during
breastfeeding
Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; DBS, dried blood
spot; PCR, polymerase chain reaction; PMTCT, prevention of mother-to-child
transmission.
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Because of these limitations, countries already planning to
prospectively and routinely measure rates of early mother-
to-child transmission of HIV at 6 weeks postpartum and to
follow up infants who were positive by enzyme-linked im-
munosorbent assay but negative by PCR for 18 months to
determine whether the child becomes infected may consider
integrating HIVDR surveillance as a nested study [40–42].
However, countries that are not planning to engage in such
PMTCT effectiveness studies are strongly encouraged to im-
plement this protocol, which provides relevant data by using
a simple and low-cost approach.
CONCLUSIONS
Increased use of NNRTIs in pregnant and breastfeeding
women will result in fewer HIV-infected children. However,
among children infected despite PMTCT, a substantial pro-
portion will have NNRTI-resistant virus, potentially com-
promising response to NNRTI-based ART. Expansion of
PMTCT options may lead to changing patterns and prevalences
of HIVDR in children infected when PMTCT regimens fail;
this protocol will provide countries with data to monitor these
changes in infants aged ,18 months.
Additionally, the survey will provide information about
HIVDR risks related to pretreatment ARV exposures and pro-
vide insight into HIVDR consequences of real-world PMTCT
implementaion.
Finally, this survey provides an opportunity to map use of
PMTCT and its record-keeping system and supports corrective
actions, if necessary. If information regarding previous ARV ex-
perience is reported as ‘‘unknown’’ for many children and high
levels of HIVDR are detected in this group, recommendations
such as targeted early virologic monitoring (where feasible)
and baseline genotypic testing (if possible) may be explored.
Overall, the evaluation of HIVDR prevalence to specific ARVs
will support decision making about pediatric ART guidelines.
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